Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Topakian, R; Brainin, M; Eckhardt, R; Kiechl, S; Ahmed, N; Ferrari, J; Iglseder, B; Wahlgren, NG; Lang, W; Fazekas, F; Willeit, J; Aichner, FT.
Thrombolytic therapy for acute stroke in Austria: data from the Safe Implementation of Thrombolysis in Stroke (SITS) register.
Eur J Neurol. 2011; 18(2):306-311
Doi: 10.1111/j.1468-1331.2010.03141.x
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Fazekas Franz
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Background: We aimed at determining the safety and efficacy of IV alteplase in Austrian versus non-Austrian centres as documented in the Internet-based registers Safe Implementation of Thrombolysis for Stroke - MOnitoring STudy (SITS-MOST) and - International Stroke Thrombolysis Register (SITS-ISTR). Methods: We analysed patient data entered in the registers SITS-MOST and SITS-ISTR in the period December 2002 to 15 November 2007. Results: Compared to the non-Austrian cohort (n = 15153), the Austrian cohort (n = 896) was slightly older [median, interquartile range (IQR): 70, 60-77 years vs. 69, 60-76 years, P = 0.05] and included more women (44.6% vs. 41.0%, P = 0.03). Austrian patients had a significantly shorter stroke onset-to-treatment time (OTT; median, IQR: 135, 105-160 min vs. 145, 115-170 min, P < 0.0005). Symptomatic intracerebral haemorrhages were observed in 1.6% of Austrian and 1.7% of non-Austrian patients (P = 0.82). At 3 months, 50.8% of Austrian and 53.0% of non-Austrian patients were independent (P = 0.23), but death was less frequent in Austrian patients (12.1% vs. 14.9%, P = 0.03). Multivariate analyses adjusted for demographic and baseline characteristics confirmed lower mortality at 3 months in the Austrian cohort (odds ratio 0.81, 95% confidence intervals 0.71-0.92, P = 0.001). Longer OTT was associated with increased mortality at 3 months, with a hazard ratio of 1.02 (95% CI 1.01-1.03; P = 0.005) for each 10-min increase in OTT. Conclusions: The implementation of intravenous alteplase for acute stroke has been safe and efficacious in Austrian centres. OTT and mortality were significantly lower in Austrian patients compared to non-Austrian SITS centres.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged -
- Aged -
- Female -
- Fibrinolytic Agents - therapeutic use
- Humans -
- Male -
- Middle Aged -
- Registries -
- Stroke - drug therapy
- Thrombolytic Therapy - statistics and numerical data
- Tissue Plasminogen Activator - therapeutic use
- Treatment Outcome -
- Find related publications in this database (Keywords)
- mortality
- outcome
- safety
- stroke
- thrombolysis